← Companies|Adaptive Biotechnologies
AD

Adaptive Biotechnologies

ADPT·NASDAQSeattle WAFounded 2009800 employees
Small CapbiotechPublicOncologyImmunology
Platform: clonoSEQ Immuno
Market Cap
$1.5B
All Drugs
2
Clinical Trials
4
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (ADPT)
Loading ADPT stock data...
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
TalamavacamtenADP-8484Phase 1/21Gene EditingIL-17ABCL-2iMyelofibrosisSchizophrenia
ADP-7169ADP-7169Approved3Gene TherapyLAG-3Anti-AβAtopic Derm
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (3)
2028-04-03
Talamavacamten Ph2 Data
Myelofibrosis
Ph2 Data
2028-05-15
ADP-7169 Ph3 Readout
Atopic Derm
Ph3 Readout
2029-12-09
ADP-7169 Ph3 Readout
Atopic Derm
Ph3 Readout